Evaluation of a third-generation screening assay for anti-hepatitis C virus(anti-HCV) anti-bodies. Comparison of second- and third-generation screening assays and interpretation of discrepant cases.

DOI
  • Nishino Kazuma
    Department of Transfusion Medicine, Toyama Medical and Pharmaceutical University Hospital
  • Higuchi Kiyohiro
    Department of Transfusion Medicine, Toyama Medical and Pharmaceutical University Hospital
  • Michino Junko
    Department of Transfusion Medicine, Toyama Medical and Pharmaceutical University Hospital
  • Tabata Sachiyo
    Department of Transfusion Medicine, Toyama Medical and Pharmaceutical University Hospital
  • Yasumura Satoshi
    Department of Transfusion Medicine, Toyama Medical and Pharmaceutical University Hospital
  • Watanabe Akiharu
    Department of Transfusion Medicine, Toyama Medical and Pharmaceutical University Hospital

Bibliographic Information

Other Title
  • 第三世代ＨＣＶ抗体測定キットの有用性の検討　第二世代ＨＣＶ抗体との比較およびかい離例の解析
  • COMPARISON OF SECOND-AND THIRD-GENERATION SCREENING ASSAYS AND INTERPRETATION OF DISCREPANT CASES
  • 第二世代HCV抗体との比較および乖離例の解析

Search this article

Description

To evaluate a third-generation (gen.) screening assay (ELISA 3.0) for anti-HCV, we investigated the sensitivity of this commercial kit in comparison with that of a second gen. -assay (PHA 2.0) on 532 sequential specimens. Among the 532 sera tested between January and February 1995, 61 (11.5%) exhibited a reactivity in second- and third-gen. assays, 5 (0.9%) were weakly positive in ELISA 3.0 and negative in PHA 2.0, and only 1 sample (0.2%) was negative in ELISA 3.0 and positive in PHA 2.0. These 6 discrepant specimens were examined for viral peptide antigens by confirming assays (single PHA and RIBA HCV 3.0). Comparing the confirmation patterns on these sera revealed that the enhanced sensitivity of third-gen. assays is mainly due to an increment reactivity of core antigen (c22p) or NS3 (c33c), and not to the addition of NS5 antigen. None of them proved to be HCV RNA-positive by PCR. These results indicate that there are few advantages to screening patients with chronic HCV infection with the third-gen. assay as compared with the second-gen. assay.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390282679885532928
  • NII Article ID
    130003706917
  • DOI
    10.3925/jjtc1958.41.353
  • ISSN
    18838383
    05461448
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top